DXCM monthly performance report
Monthly DXCM research: returns, drawdown, relative strength, seasonality, and key stats.
DXCM monthly report
—
Key takeaways
- Dexcom (DXCM) closed September 2026 at $84.53, down 7.17% for the month and +8.37% over the trailing 12 months.
- Year-to-date, DXCM is +27.36%, outperforming the S&P 500 which has returned +12.32% YTD.
- The stock is trading +19.80% versus its 200-day moving average ($70.56), a bullish technical signal.
- Over the past three years, DXCM has underperformed the S&P 500 by −90.92%, with a relative strength index reading of 47.1.
- Win rate over the trailing 39 months stands at 46.2% — 18 positive months versus 21 negative months.
Dexcom ended September 2026 at $84.53, posting a monthly return of −7.17%. The S&P 500 returned −0.14% over the same window, leaving relative performance at −7.03%.
The current quarter stands at +25.51% (Q3 2026 (QTD)), while medium-term trend remains constructive: price is +19.80% versus the 200-day moving average ($70.56).
Year-to-date, DXCM is +27.36% against SPY +12.32%, a gap of +15.04%. The stock is currently −8.71% below its 52-week high, with maximum 3-year drawdown at −60.95%.
| Period | DXCM | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | −3.83% | −0.55% | −3.28% |
| 1 Week | −5.33% | −0.44% | −4.89% |
| 1 Month | −7.17% | −0.14% | −7.03% |
| 3 Months | +16.16% | +1.17% | +14.99% |
| 6 Months | +15.67% | +11.80% | +3.87% |
| YTD | +27.36% | +12.32% | +15.04% |
| 12 Months | +8.37% | +18.05% | −9.68% |
| 3 Years | −18.99% | +71.92% | −90.92% |
| Rank | Month | Return |
|---|---|---|
| #1 | Nov 2023 | +30.05% |
| #2 | Jul 2026 | +23.90% |
| #3 | May 2026 | +23.83% |
| #4 | Mar 2024 | +20.54% |
| #5 | May 2025 | +20.20% |
| Rank | Month | Return |
|---|---|---|
| #1 | Jul 2024 | −40.18% |
| #2 | Mar 2025 | −22.72% |
| #3 | Aug 2023 | −18.93% |
| #4 | Mar 2026 | −14.48% |
| #5 | Oct 2025 | −13.48% |
| Quarter | Return |
|---|---|
| Q2 2025 | +27.82% |
| Q3 2025 | −22.91% |
| Q4 2025 | −1.37% |
| Q1 2026 | −5.38% |
| Q2 2026 | +7.25% |
| Q3 2026 (QTD) | +25.51% |
| Year | Return |
|---|---|
| 2023 | +9.58% |
| 2024 | −37.33% |
| 2025 | −14.66% |
| 2026 | +27.36% |
| Metric | Value |
|---|---|
| 52-Week High | $92.59 (2026-08-24) |
| 52-Week Low | $54.11 (2025-11-07) |
| Current Price | $84.53 |
| 200-Day Moving Average | $70.56 |
| Price vs 200DMA | +19.80% |
| 3-Year Maximum Drawdown | −60.95% (2025-11-10) |
| Current Drawdown from 52W High | −8.71% |
| RS metric | Value |
|---|---|
| RS Index (3-year, rebased to 100) | 47.1 |
| 3-Year Excess Return vs S&P 500 | −90.92% |
| RS Peak | 117 (Apr 2024) |
| RS Trough | 33 (May 2026) |
| Status | Underperforming Benchmark |
Frequently asked questions
What was DXCM's return for this report period?
DXCM returned −7.17% in the latest monthly window ending 2026-09-08.
Has DXCM outperformed SPY year to date?
YTD DXCM: +27.36% vs SPY: +12.32%.
What is DXCM's 12-month return?
+8.37% over the trailing 12 months.
Is DXCM above or below its 200-day moving average?
Price is +19.80% versus 200DMA ($70.56).
What is the maximum drawdown in the 3-year window?
−60.95% on 2025-11-10.